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 Review Article 
Neurotransmitters – A biochemical view 
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M Ahmed4 
Abstract: 
The neurotransmission at most if not all synapses is chemical and is of great biochemical, 
physiological and pharmacological importance. Neurons communicate with each other at synapses 
by a process called synaptic transmission in which the release of small quantities of chemical 
messengers, called neurotransmitters that alter the electrical activity of neurons after they interact 
with receptors on post-synaptic cell surfaces. This review gives a biochemical view on the nature of 
neurotransmitters and presents the biochemical chart and the medical relevance of the most 
important neurotransmitters. 
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he central nervous system (CNS) 
operates by a fine-tuned balance 
between excitatory and inhibitory 
signaling1. Complex brain functions, such as 
learning and memory, are believed to involve 
changes in the efficiency of communication 
between nerve cells. Therefore, the 
elucidation of the molecular mechanisms that 
regulate synaptic transmission, the process of 
intercellular communication, is an essential 
step towards understanding nervous system 
function2. The release of neurotransmitter via 
regulated exocytosis is the primary mode of 
communication in the nervous system3. 
Neurotransmitters are chemical substances 
which relay amplify and modulate signals 
between a neuron and another cell; i.e. 
involved in the transmission of an impulse 
from one cell to another3. The major 
categories of substances that act as 
neurotransmitters are1 amino acids or amino 
acid derivatives (primarily glutamic acid, 
GABA, aspartic acid and glycine)2, 
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peptides (vasopressin, adrenocortitrophic 
hormone (ACTH), melanocyte stimulating 
hormone (MSH), somatostatin, neurotensin, 
β-endorphin, substance P, enkephalins etc.) 
and3 monoamines (biogenic amines) 
(norepinephrine, dopamine, histamine, and 
serotonin) in addition to acetylcholine4,5. 
Neurotransmitters derived from amino acids 
include g-aminobutyrate, 5-
hydroxytryptamine (serotonin), dopamine, 
norepinephrine, and epinephrine. Many drugs 
used to treat neurologic and psychiatric 
conditions affect the metabolism of these 
neurotransmitters6. 
Arginine is also the precursor of the 
intercellular signaling molecule nitric oxide 
(NO) that serves as a neurotransmitter 
(modulation of transmission), smooth muscle 
relaxant, and vasodilator. Synthesis of NO, 
catalyzed by NO synthase, involves the 
NADPH-dependent reaction of L-arginine 
with O2 to yield L-citrulline and NO6. 
g-Aminobutyrate 
g-Aminobutyrate (GABA) functions in brain 
tissue as an inhibitory neurotransmitter by 
altering trans-membrane potential differences. 
It is formed by decarboxylation of L-
glutamate, a reaction catalyzed by L-
glutamate decarboxylase5 which needs 
pyridoxal phosphate (active vitamine B6) as a 
coenzyme. This process converts the principal 
excitatory neurotransmitter (glutamate) into 
T
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the principal inhibitory one (GABA)7,8.  
Transamination of g-aminobutyrate forms 
succinate semialdehyde, which may then 
undergo reduction to g-hydroxybutyrate, a 
reaction catalyzed by L-lactate 
dehydrogenase, or oxidation to succinate and 
thence via the citric acid cycle to CO2 and 
H2O. A rare genetic disorder of GABA 
metabolism involves a defective GABA 
aminotransferase, an enzyme that participates 
in the catabolism of GABA subsequent to its 
postsynaptic release in brain tissue6.  The 
brain's principal inhibitory 
neurotransmitterGABA, along with serotonin 
and norepinephrine, is one of several 
neurotransmitters that appear to be involved 
in the pathogenesis of anxiety and mood 
disorders9.  
There are two principal subtypes of 
postsynaptic GABA receptor complexes, the 
GABA-A and GABA-B receptor complexes. 
Activation of the GABA-B receptor by 
GABA causes neuronal membrane 
hyperpolarization and a resultant inhibition of 
neurotransmitter release. In addition to 
binding sites for GABA, the GABA-A 
receptor has binding sites for 
benzodiazepines, barbiturates, and 
neurosteroids. GABA-A receptors are coupled 
to chloride ion channels; activation of the 
receptor induces increased inward chloride 
ion flux, resulting in membrane 
hyperpolarization and neuronal inhibition9. 
Other inhibitory neurotransmitters include 
glycine, β-alanine, and taurine as well as 
histamine while, the dicarboxylic amino acids 
glutamate and aspartate are excitatory ones10. 
The membranes of nerve cells contain well-
studied ion channels that are responsible for 
the action potentials generated across the 
membrane. The activity of some of these 
channels is controlled by neurotransmitters; 
hence, channel activity can be regulated. One 
ion can regulate the activity of the channel of 
another ion. For example, a decrease of 
Ca+2concentration in the extracellular fluid 
increases membrane permeability and 
increases the diffusion of Na+. This 
depolarizes the membrane and triggers nerve 
discharge, which may explain the numbness, 
tingling, and muscle cramps symptoms of a 
low level of plasma Ca2+.6 
Neurons (nerve cells) and certain muscle 
cells are specialized to generate and conduct a 
particular type of electric impulse, the action 
potential. This alteration of the electric 
potential across the cell membrane is caused 
by the opening and closing of certain voltage-
gated ion channels11. 
Arrival of an action potential at an axon 
terminal (figure 1) leads to opening of 
voltage-sensitive Ca+2channels and an influx 
of Ca2+, causing a localized rise in the 
cytosolic Ca+2concentration in the axon 
terminus. The rise in Ca+2in turn triggers 
fusion of small vesicles containing 
neurotransmitters with the plasma membrane, 
releasing neurotransmitters from this 
presynaptic cell into the synaptic cleft, the 
narrow space separating it from postsynaptic 
cells. It takes about 0.5 millisecond (ms) for 
neurotransmitters to diffuse across the 
synaptic cleft and bind to a receptor on the 
postsynaptic cell.  Binding of 
neurotransmitter triggers opening or closing 
of specific ion channels in the plasma 
membrane of postsynaptic cells, leading to 
changes in the membrane potential at this 
point. 
 
Figure 1: Arrival of an action potential at an axon terminal 
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A single axon in the central nervous system 
can synapse with many neurons and induce 
responses in all of them simultaneously. Thus 
neurons use changes in the membrane 
potential, the action potentials, to conduct 
signals along their length, and small 
molecules, the neurotransmitters, to send 
signals from cell to cell11. 
Synapses are the junctions where neurons 
release a chemical neurotransmitter that acts 
on a postsynaptic target cell, which can be 
another neuron or a muscle or gland cell. 
Neurotransmitter receptors fall into two broad 
classes: ligand-gated ion channels, which 
open immediately upon neurotransmitter 
binding, and G protein–coupled receptors. 
Neurotransmitter binding to a G protein–
coupled receptor induces the opening or 
closing of a separate ion channel protein over 
a period of seconds to minutes6,11. 
 
Numerous small molecules function as 
neurotransmitters at various synapses. With 
the exception of acetylcholine (figure 2), the 
neurotransmitters shown in Figure 3 are 
amino acids or derivatives of amino acids. 
Nucleotides such as ATP and the 
corresponding nucleosides, which lack 
phosphate groups, also function as 
neurotransmitters. Each neuron generally 
produces just one type of neurotransmitter11. 
All the “classic” neurotransmitters are 
synthesized in the cytosol and imported into 
membrane-bound synaptic vesicles within 
axon terminals, where they are stored. Similar 
to the accumulation of metabolites in plant 
vacuoles, this proton concentration gradient 
(vesicle lumen cytosol) powers 
neurotransmitter import by ligand-specific 
H+-linked antiporters in the vesicle 
membrane. For example, acetylcholine is 
synthesized from acetyl coenzyme A (acetyl 
CoA), an intermediate in the degradation of 
glucose and fatty acids, and choline in a 
reaction catalyzed by choline 
acetyltransferase11: 
 
               Figure 2: Synthesis of acetylcholine from acetyl-CoA and choline 
 
Synaptic vesicles take up and concentrate 
acetylcholine from the cytosol against a steep 
concentration gradient, using an 
H+/acetylcholine antiporter in the vesicle 
membrane. Curiously, the gene encoding this 
antiporter is contained entirely within the first 
intron of the gene encoding choline 
acetyltransferase, a mechanism conserved 
throughout evolution for ensuring coordinate 
expression of these two proteins. Different 
H+/neurotransmitter antiport proteins are used 
to import other neurotransmitters into 
synaptic vesicles11. 
Neurotransmitters are released by exocytosis, 
a process in which neurotransmitter-filled 
synaptic vesicles fuse with the axonal 
membrane, releasing their contents into the 
synaptic cleft.  
 
The exocytosis of neurotransmitters from 
synaptic vesicles involves vesicle-targeting 
and fusion events similar to those that occur 
during the intracellular transport of secreted 
and plasma-membrane proteins. Two features 
critical to synapse function differ from other 
secretory pathways: (a) secretion is tightly 
coupled to arrival of an action potential at the 
axon terminus, and (b) synaptic vesicles are 
recycled locally to the axon terminus after 
fusion with the plasma membrane11.  
Acetylcholine (ACh) was the neurotransmitter 
first discovered, at the beginning of the last 
century. It binds to two types of receptor; the 
nicotinic ACh receptor responds to the 
alkaloid nicotine contained in tobacco, and 
the muscarinic ACh receptors (of which 
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Their name is derived from the alkaloid 
muscarine, which is found in the flyagaric 
mushroom (Amanita muscaria), for example. 
Like ACh, muscarine is bound at the receptor, 
but in contrast to ACh, it is not broken down 
and therefore causes permanent stimulation of 
muscle12. 
The acetylcholine receptor is a ligand-gated 
sodium channel that initiates the flow of 
sodium into the cell (and potassium out) when 
the receptor binds the neurotransmitter, 
acetylcholine. Voltage-gated channels open 
and close in response to changes in the 
membrane potentials. The acetylcholine 
receptor is also voltage-gated. When the 
membrane potential becomes positive, it 
opens the channel further, increasing the rate 
of membrane depolarization13. Following 
their release from a presynaptic cell, 
neurotransmitters must be removed or 
destroyed to prevent continued stimulation of 
the postsynaptic cell. Signaling can be 
terminated by diffusion of a transmitter away 
from the synaptic cleft, but this is a slow 
process. Instead, one of two more rapid 
mechanisms terminates the action of 
neurotransmitters at most synapses. Signaling 
by acetylcholine is terminated when it is 
hydrolyzed to acetate and choline by 
acetylcholinesterase, an enzyme localized to 
the synaptic cleft. Choline released in this 
reaction is transported back into the 
presynaptic axon terminal by a Na+/choline 
symporter and used in synthesis of more 
acetylcholine. The operation of this 
transporter is similar to that of the Na+-linked 
symporters used to transport glucose into cells 
against a concentration gradient. With the 
exception of acetylcholine, all the 
neurotransmitters are removed from the 
synaptic cleft by transport into the axon 
terminals that released them. Thus these 
transmitters are recycled intact. Transporters 
for GABA, norepinephrine, dopamine, and 
serotonin were the first to be cloned and 
studied. These four transport proteins are all 
Na+-linked symporters. They are 60–70 
percent identical in their amino acid 
sequences, and each is thought to contain 12 
transmembrane α helices. As with other Na+ 
symporters, the movement of Na+ into the cell 
down its electrochemical gradient provides 
the energy for uptake of the neurotransmitter. 
To maintain electroneutrality, Cl+ is often 
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transported via an ion channel along with the 
Na+ and neurotransmitter. 
The neurotransmitters released from 
presynaptic neurons may bind to an excitatory 
receptor on the postsynaptic neuron, thereby 
opening a channel that admits Na+ ions or 
both Na+and K+ ions11.  
The acetylcholine receptor is one of many 
excitatory receptors, and opening of such ion 
channels leads to depolarization of the 
postsynaptic plasma membrane, promoting 
generation of an action potential11,13. In 
contrast, binding of a neurotransmitter to an 
inhibitory receptor on the postsynaptic cell 
causes opening of K+ or Cl+ channels, leading 
to an efflux of additional K+ ions from the 
cytosol or an influx of Cl+ ions. In either case, 
the ion flow tends to hyperpolarize the plasma 
membrane, which inhibits generation of an 
action potential in the postsynaptic cell11. 
The neuromuscular junction consists of a 
single nerve terminal separated from the post-
synaptic region by the synaptic cleft (figure 
4). The motor end plate is the specialized 
portion of the muscle membrane involved in 
the junction. Junctional folds are prominent; 
they contain a high density of AChRs in close 
proximity to the nerve terminal. 
 
 
             Figure 4: A chemical synapse. 
 
 
The overall process at the junction can be 
considered to take place in six steps: 
1. Synthesis of acetylcholine occurs in 
the cytosol of the nerve terminal 
(terminal knob). In a reaction 
catalyzed by choline acetyl 
transferase. 
2. Acetyl choline is then incorporated 
into small membrane-bound particles 
called synaptic vesicles and stored 
there. 
3. Release of acetylcholine from these 
vesicles into synaptic cleft is the next 
step. This occurs by exocytosis, which 
involves fusion of the vesicles with 
the pre-synaptic membranes. In the 
resting state, single quanta (~ 10,000 
transmitter molecules, probably 
corresponding to the contents of one 
synaptic vesicle) are released 
spontaneously, resulting in small end 
plate potentials. When a nerve ending 
is depolarized by transmission of a 
nerve impulse, this process opens 
voltage-sensitive Ca++ channels, 
permitting an influx of Ca+2from 
synaptic space (cleft) into the nerve 
terminal. This Ca+2plays an essential 
role in the exocytosis that releases 
acetylcholine (contents of 
approximately 200 vesicles) into the 
synaptic space. 
4. The released acetylcholine diffuses 
across the synaptic cleft to its 
receptors in the junctional folds. When 
2 molecules of acetylcholine bind to a 
receptor, it undergoes a 
conformational change, opening a 
channel in the receptor that permits a 
flux of cations (Na+) across the 
membrane. The consequent entry of 
Na+ results in depolarization of the 
muscle membrane, forming end plate 
potential. This in turns depolarizes the 
adjacent muscle membrane, and action 
potentials are generated and 
transmitted along the fiber, resulting 
in contraction. Thus, AChR 
(acetylcholine receptor) is a 
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transmitter-gated ion channel. (N.B 
some neurotransmitters can inhibit the 
post-synaptic membrane by altering its 
permeability to Cl- or K+). 
5. When the channel closes, the 
acetylcholine dissociates and is 
hydrolyzed by acetylcholine esterase 
to acetate and choline. This important 
enzyme is present in high 
concentrations in basal lamina of the 
synaptic space. 
6. Choline is recycled into the nerve 
terminal by an active transport 
mechanism, where it can be used 
again for synthesis of acetylcholine5,14. 
Catecholamines: 
Catecholamines (epinephrine, norepinephrine, 
and dopamine) are amine hormones derived 
from the amino acid tyrosine. They act as 
neurotransmitters in the central and peripheral 
nervous systems. The catecholamine 
hormones travel in the blood to their target 
cell and bind to the plasma membrane at 
specific receptor sites. Binding of 
catecholamine activates the cyclic AMP 
second messenger system and alters enzyme 
activity or membrane permeability. 
The fight-or-flight response begins with 
activation of the sympathetic nervous system 
(SNS), a branch of the autonomic nervous 
system (ANS). Immediately following 
stressor exposure, the SNS responds with the 
release of the catecholamines epinephrine and 
norepinephrine from sympathetic neurons and 
the adrenal medulla, located in the center of 
the adrenal glands. 
The responses to catecholamines are similar 
whether they are released from nerves or from 
the adrenal medulla. However, 
catecholamines released from the adrenal 
gland are rapidly metabolized and thus show 
more limited effects. Norepinephrine works 
both as a neurotransmitter in the CNS and as a 
hormone when it is released by the adrenal 
gland with epinephrine. Circulating and 
neurally released norepinephrine binds to 
receptors called alpha-receptors, identified as 
alpha1 and alpha 2 receptors. Binding to 
alpha1 receptors present on most vascular 
smooth muscle cells causes the muscles to 
contract, leading to a decrease in blood flow 
to organs supplied by those vascular beds. By 
this means, sympathetic activation causes a 
decrease in blood flow to the organs of the 
gastrointestinal (GI) tract, the skin, and the 
kidneys. Decreasing blood flow to these 
organs ensures maximum blood flow to the 
brain, heart, and skeletal muscles in times of 
stress. Norepinephrine also binds to receptors 
on the smooth muscle of the GI tract, causing 
relaxation of the muscle and thereby slowing 
digestion and GI motility. Circulating and 
neurally released epinephrine acts by binding 
not only to alpha-receptors, but also to beta-
receptors, identified as β1 and β2. By binding 
to β1 receptors on the heart, epinephrine 
causes an increase in heart rate and an 
increase in cardiac contractility, both of which 
serve to increase the cardiac output during 
stress. Epinephrine binding to β2 receptors in 
the liver and skeletal muscle causes an 
increase in glucose release, resulting in 
increased glucose available for all cells to use 
if fight or flight is necessary. Epinephrine 
binding to β2 receptors present on bronchiolar 
smooth muscle increases airflow to the lungs 
by relaxing the muscle, thereby opening up 
the air passages and facilitating oxygenation 
of blood for tissues that may be called on 
during a stressful situation15. 
The secretion of prolactin from the anterior 
pituitary is under the control of two opposing 
hypothalamic hormones: prolactin-inhibitory 
hormone (PIH) and prolactin-stimulatory 
hormone. PIH appears to be the 
neurotransmitter dopamine thus, a decrease in 






Serotonin (5-hydroxytryptamine or 5-HT) is a 
monoamine neurotransmitter synthesized in 
Mohammed H F Shalayel et al.                                             Neurotransmitters – A biochemical view 
 
173© Sudan JMS Vol. 4, No. 2, June 2009                   
 
 
serotonergic neurons in the central nervous 
system and enterochromaffin cells in the 
gastrointestinal tract. Serotonin is believed to 
play an important part of the biochemistry of 
depression, migraine, bipolar disorder and 
anxiety. It is also believed to be influential on 
sexuality and appetite. Serotonin is found 
extensively in the human gastrointestinal 
tract, or gut, as well as in the blood stream. In 
the body, serotonin is synthesized from the 
amino acid tryptophan by various enzymes as 
shown in the reaction below. Serotonin taken 
orally does not pass into the serotonergic 
pathways of the central nervous system 
(CNS). This is due to the blood-brain barrier's 
preventing serotonin in the blood stream from 
affecting serotonin levels in the brain. 
Moreover, the neurotransmitter serotonin 
plays a key role in stimulating neurons that 




Purines have long been known for their roles 
in extracellular signaling. One of the most 
interesting functions to come to light recently 
has been the involvement, particularly of 
adenosine 5’-triphosphate (ATP), as a 
neurotransmitter in the central and the 
sympathetic nervous system.  ATP is stored in 
and released from synaptic nerve terminals, 
like other neurotransmitters, and is known to 
act postsynaptically via specific rapidly-
conducting, ligand-gated ion channels, the P2X 
receptors.  Another interesting feature is the 
discovery that ATP is widely found to be a 
“co-transmitter” at the same synapses in 
combination with other neurotransmitters 
such as noradrenaline, acetylcholine, and 
GABA, altering our picture of the biophysics 
and biochemistry of neurotransmission at 
these synapses17. Co-transmission has been 
described as the co-localization and co-release 
of two or more neurotransmitters upon nerve 
stimulation from the same nerve terminals, to 
act on the post-synaptic cells to carry out the 
process of neurotransmission. The actions of 
co-transmitters on the post-synaptic cells have 
been reported to be either synergistic or 
antagonistic18. 
Medical relevance: 
∑ To understand Myasthenia Gravis 
(MG), it is necessary to understand 
events occurring at neuromuscular 
junction. MG is characterized by 
recurrent episodes of muscle weakness 
after exercise; muscles supplied by 
cranial nerves are most affected. It is 
improved by administration of drugs 
that inhibit acetylcholine esterase (e.g. 
the short acting edrophonium or 
longer acting agents like 
pyridostigmine and neostigmine), a 
fact that is used in diagnosis and 
treatment. In MG, for unclear reasons, 
the body forms auto-antibodies against 
the acetylcholine receptors of the 
neuromuscular junction14. 
∑ Acondition that resembles myasthenia 
gravis is Lambert–Eaton syndrome. 
In this condition, muscle weakness is 
caused by antibodies against one of 
the Ca+2channels in the nerve endings 
at the neuromuscular junction. This 
decreases the normal Ca+2influx that 
causes acetylcholine release. 
However, muscle strength increases 
with prolonged contractions as more 
Ca+2is released19. 
∑ Acetylcholine esterase is responsible 
for the hydrolysis of acetylcholine. It 
is very important that neurotransmitter 
has a very short half-life following its 
release from the pre-synaptic neurons. 
If acetylcholine esterase is inhibited 
(by the use of a nerve gas, 
diisopropylfluorophosphate, DFP), the 
muscles of the body undergo violent 
contraction due to the continued 
presence of high concentration of 
acetylcholine and finally become 
paralyzed14. 
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∑ There are other highly toxic 
substances whose action comes from 
their disruption of normal nerve 
muscle communication. Curare is a 
powerful muscle relaxant that leads to 
paralysis and death by asphyxiation.  
Curare, used by South American 
Indians, competitively inhibits binding 
of ACh to its membrane receptor12.  
 
∑ The bacterial toxin responsible for 
botulism (clostridium botulinum) also 
causes paralysis but, it acts by 
blocking the release of acetylcholine 
from presynaptic neuron. Botulinum 
neurotoxins (BoNT, serotypes A-G) 
and tetanus neurotoxin (TeNT) are 
bacterial proteins that comprise a light 
chain (Mr ≈50) disulfide linked to a 
heavy chain (Mr ≈100). By inhibiting 
neurotransmitter release at distinct 
synapses, these toxins cause two 
severe neuroparalytic diseases, tetanus 
and botulism. The cellular and 
molecular modes of action of these 
toxins have almost been deciphered. 
After binding to specific membrane 
acceptors, BoNTs and TeNT are 
internalized via endocytosis into nerve 
terminals. Subsequently, their light 
chain (a zinc-dependent 
endopeptidase) is translocated into the 
cytosolic compartment where it 
cleaves one of three essential proteins 
involved in the exocytotic machinery: 
vesicle associated membrane protein 
(also termed synaptobrevin), syntaxin, 
and synaptosomal associated protein 
of 25 kDa[20]. There are local 
anesthetics such as procaine that have 
similar mode of action (blocking the 
release of acetylcholine from 
presynaptic neuron)14. 
∑ Parkinson's disease is caused by 
degeneration of the cells of the 
substantia nigra (atrophic changes in 
the substantia nigra and depletion of 
neurons in the locus coeruleus),  
resulting in a deficiency of dopamine 
in such cells. Levo dopa (L-dopa) is 
an effective therapy as it can cross the 
blood brain barrier and is converted to 
dopamine in the brain10.   
∑ Biochemical changes in brains of 
patients with Alzheimer's disease and 
senile dementia include reduced 
activity of acetylcholineesterase and 
choline-acetyltransferase, indicating 
reduced activity in the 
acetylcholinergic system. There is 
also, however, reduced activity in the 
dopamine, noradrenaline and 5-
hydroxytryptamine system21. 
∑ Autoimmunity to glutamate 
decarboxylase (GAD) appears to cause 
the stiff-man syndrome, a disease 
characterized by fluctuating but 
progressive muscle rigidity and 
painful muscle spasms, presumably 
due to GABA deficiency. It is 
interesting that GAD is also present in 
structures resembling synaptic vesicles 
in the insulin-secreting β cells of the 
pancreas, and GABA may be a 
paracrine mediator in the islets19. 
∑ The classical dopamine hypothesis of 
schizophrenia postulates a 
hyperactivity of dopaminergic 
transmission at the D2 receptor and 
there is a direct evidence of increased 
stimulation of D2 receptors by 
dopamine in schizophrenia, consistent 
with increased phasic activity of 
dopaminergic neurons22.   
Biochemical chart and medical relevance of 
the major neurotransmitters are 
summarized10,19,23,24 in table 1,2 and 3. 
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